(Q35606005)

9 August 2017

1 reference

title

Bone loss and the evolving role of bisphosphonate therapy in prostate cancer (English)

1 reference

9 August 2017

1 reference

1

Celestia S Higano

1 reference

9 August 2017

language of work or name

1 reference

1 September 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

21

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

392-398

1 reference

Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Medicare spending for injured elders: are there opportunities for savings?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Mortality and institutionalization following hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

The incidence of vertebral fractures in men and women: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Prostatic Cancer: Treatment with Long-acting LHRH Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men**Supported in part by the National Cancer Institute of Canada; Hoechst AG, Frankf

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Comparison of goserelin and leuprolide in combined androgen blockade therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Antiandrogen monotherapy: indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Osteoporosis due to cancer treatment: pathogenesis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Low bone mineral density in hormone-naïve men with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Resistance exercise and bone turnover in elderly men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Does hormone-replacement therapy prevent fractures in early postmenopausal women?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900143-1

1 reference

7 January 2021

10.1016/S1078-1439(03)00143-1

Identifiers

DOI

1 reference

9 August 2017

1 reference